Compare NAC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NAC | ZYME |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1998 | 2022 |
| Metric | NAC | ZYME |
|---|---|---|
| Price | $11.72 | $23.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $38.90 |
| AVG Volume (30 Days) | 335.6K | ★ 510.3K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $10.94 | $11.86 |
| 52 Week High | $12.25 | $29.75 |
| Indicator | NAC | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 26.23 | 41.61 |
| Support Level | $11.64 | $22.20 |
| Resistance Level | $12.04 | $23.66 |
| Average True Range (ATR) | 0.08 | 0.86 |
| MACD | -0.04 | -0.26 |
| Stochastic Oscillator | 0.05 | 12.47 |
Nuveen California Quality Municipal Income Fund is a closed-end fixed income mutual fund that prominently invests in tax-exempt municipal bonds from California. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. Its portfolio mainly includes investment-grade municipal securities of California. The fund targets various sectors such as healthcare, utilities, transportation, and consumer staples.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.